<--- Back to Details
First PageDocument Content
Belimumab / Medicine / Systemic lupus erythematosus / Human Genome Sciences / Lupus erythematosus / B-cell activating factor / Food and Drug Administration / Autoimmune disease / Anatomy / Monoclonal antibodies / Health
Belimumab
Medicine
Systemic lupus erythematosus
Human Genome Sciences
Lupus erythematosus
B-cell activating factor
Food and Drug Administration
Autoimmune disease
Anatomy
Monoclonal antibodies
Health

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 56,62 KB

Share Document on Facebook

Similar Documents

CONTACT: Media: Charlene McGrady, extMDS Pharma Services Scientist to Discuss Development of Biosimilar Monoclonal Antibodies at EGA Symposium

DocID: 1vhgc - View Document

ABIRISK ABIRISK Project Officially Started A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments for

DocID: 1v3WA - View Document

Celartia Protocols Hybridoma Cell culture with Petaka-HOT (High Oxygen Turnover, orange port) Production of Monoclonal Antibodies Petaka-HOT allows culturing non adherent

DocID: 1uTpm - View Document

INTERNSHIP PROPOSAL Institute and Group: IBS group HIV and persistent human viruses Supervisor: Pascal Poignard Email: Research project title: Human monoclonal antibodies: a new therapeutic strategy

DocID: 1uPEI - View Document

Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT – Expands Company’s Therapeutic Pipeline for Infectious Diseases – Cambridge, MA – December 2, 2013 – Visterra,

DocID: 1ujGa - View Document